Table 2.
Baseline clinical characteristics of type 1 diabetes patients presenting with diabetic ketoacidosis
| Characteristics | Overall (n = 823) | SGLT2i(+) (n = 139) | SGLT2i(−) (n = 684) | P‐value (SGLT2i[+] vs SGLT2i[−]) |
|---|---|---|---|---|
| Sex, n (%) | ||||
| Male | 380 (46.2) | 58 (41.7) | 322 (47.1) | 0.249 |
| Female | 443 (53.8) | 81 (58.3) | 362 (52.9) | |
| Age | ||||
| Mean (years) | 45.6 ± 20.7 | 50.3 ± 15.5 | 44.7 ± 21.5 | 0.002 |
| Distribution, n (%) | ||||
| <25 | 147 (17.9) | 8 (5.8) | 139 (20.3) | <0.001 |
| 25–44 | 232 (28.2) | 49 (35.3) | 183 (26.8) | |
| 45–64 | 271 (32.9) | 54 (38.8) | 217 (31.7) | |
| ≥65 | 173 (21.0) | 28 (20.1) | 145 (21.2) | |
| BMI | ||||
| Mean (kg/m2) | 21.5 ± 4.6 | 24.5 ± 4.9 | 21.0 ± 4.5 | <0.001 |
| Distribution, n (%) | ||||
| <25 | 665 (80.8) | 86 (61.9) | 579 (84.6) | <0.001 |
| ≥25 | 158 (19.2) | 53 (38.1) | 105 (15.4) | |
| Insulin regimen, n (%) | ||||
| MDI | 706 (85.8) | 124 (89.2) | 582 (85.1) | 0.205 |
| CSII | 117 (14.2) | 15 (10.8) | 102 (14.9) | |
Data shown as mean ± standard deviation. Body mass index (BMI) is weight in kilograms divided by the square of height in meters.
CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injection; SGLT2i(+), patients treated with sodium–glucose cotransporter 2 inhibitors; SGLT2i(−), patients treated without sodium–glucose cotransporter 2 inhibitors.